Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence

Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence

Megan N Gower,1 Lindsay R Ratner,1 Alexis K Williams,1 Joseph S Rossi,2 George A Stouffer,2,3 Craig R Lee1,3 1Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA; 2Division of Cardiology, UNC School of Medicine, Chapel Hill, NC, USA; 3UNC...

Full description

Bibliographic Details
Main Authors:	Gower MN, Ratner LR, Williams AK, Rossi JS, Stouffer GA, Lee CR
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-07-01
Series:	Pharmacogenomics and Personalized Medicine
Subjects:	percutaneous coronary intervention clopidogrel cyp2c19 precision medicine pharmacogenetics stroke
Online Access:	https://www.dovepress.com/clinical-utility-of-cyp2c19-genotype-guided-antiplatelet-therapy-in-pa-peer-reviewed-article-PGPM

Similar Items

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
by: Seyed abbas Mirabbasi, et al.
Published: (2017-07-01)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
by: Larisa H. Cavallari, et al.
Published: (2018-04-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

Development of a Multiplex and Cost-Effective Genotype Test toward More Personalized Medicine for the Antiplatelet Drug Clopidogrel
by: Hye-Eun Jeong, et al.
Published: (2014-05-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics
by: Arzu Gunes, et al.
Published: (2010-03-01)

Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example
by: Kisor DF, et al.
Published: (2021-05-01)

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial
by: Xiujin Shi, et al.
Published: (2021-06-01)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
by: Sherry-Ann Brown, et al.
Published: (2018-01-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients
by: Zhang M, et al.
Published: (2020-02-01)

Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population
by: Sagheer Ahmed, et al.
Published: (2021-03-01)

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015-12-01)

Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays
by: Giada Scantamburlo, et al.
Published: (2017-10-01)

Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine
by: Cristina Lucía Dávila-Fajardo, et al.
Published: (2019-04-01)

Association of CYP2C19*2 polymorphisms and high on-treatment platelet reactivity in acute myocardial infarction or coronary artery in-stent restenosis patients during dual antiplatelet therapy
by: Yawei Yang, et al.
Published: (2020-06-01)

Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
by: Changqing Li, et al.
Published: (2021-03-01)

CYP2A6 and CYP2B6: Sources of Variation and their Role in Nicotine Metabolism
by: Al Koudsi, Nael
Published: (2010)

CYP2A6 and CYP2B6: Sources of Variation and their Role in Nicotine Metabolism
by: Al Koudsi, Nael
Published: (2010)

The influence of CYP2C19*2 and CYP3A5*3 variants on the development of depression and effectiveness of therapy: A preliminary study
by: Rafał Świechowski, et al.
Published: (2021-10-01)

ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY?
by: S. J. Martsevich
Published: (2016-01-01)

The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
by: Teun van Gelder, et al.
Published: (2020-07-01)

CYP2D6 Genotype-Based Dose Recommendations for Risperidone in Asian People
by: Yuanxia Cui, et al.
Published: (2020-08-01)

Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients
by: Renske H. Olie, et al.
Published: (2021-09-01)

CYP2C19*2 Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese
by: Chow E, et al.
Published: (2020-01-01)

Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center
by: Jamshed J. Dalal, et al.
Published: (2016-09-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China
by: Yi Zhang, et al.
Published: (2021-01-01)

CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome
by: Mirzaev KB, et al.
Published: (2017-04-01)

Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response
by: J. E. Zhang, et al.
Published: (2017-05-01)

Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus
by: Sabina Semiz, et al.
Published: (2010-11-01)

The polymorphism of cytochrome P450 CYP2C19 and resistance to clopidogrel.
by: C. Simoglou
Published: (2017-03-01)

Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention
by: S. Ramesh, et al.
Published: (2020-11-01)

CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS
by: R. Rahmatini, et al.
Published: (2018-04-01)

Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina
by: Sabina Semiz, et al.
Published: (2011-02-01)

CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease
by: Sudhir S. Shetkar, et al.
Published: (2014-01-01)

Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
by: Santosh ePhilips, et al.
Published: (2012-03-01)

Influence of CYP2C19*2 gene variant on therapeutic response during clopidogrel treatment in patients with carotid artery stenosis
by: Bačković Dragana, et al.
Published: (2016-01-01)

CYP2C19 genotype-directed P2Y12 inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention
by: Tomasz P. Stys, et al.
Published: (2021-05-01)